Home›Nutrition & Obesity Medicine› Orforglipron tablets and capsules are bioequivalent across six dose levels in adults with obesity
Orforglipron tablets and capsules are bioequivalent across six dose levels in adults with obesityTrial Shows Orforglipron Tablets and Capsules Work the Same
Diabetes, obesity & metabolismPublished July 28, 2026Study authors: Ma Xiaosu, Li Ying Grace, Raha Sohini, Sperry David C, Coutant David E, Bhattachar ShobhaPubMed ↗NCT06440980 ↗DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Note that orforglipron tablets and capsules are bioequivalent across all tested dose levels in adults with obesity.
This Phase 1 multicenter clinical trial enrolled 429 healthy adults with obesity or overweight to evaluate the pharmacokinetic equivalence of different delivery methods for orforglipron.
The study compared orforglipron tablets against orforglipron capsules across six dose strengths (capsules: 1, 3, 6, 12, 24, 36 mg; tablets: 0.8, 2.5, 5.5, 9, 14.5, 17.2 mg). The primary outcomes were steady-state area under the concentration-time curve from 0 to 24 h (AUC) and steady-state maximum observed drug concentration (Cmax).
Bioequivalence was demonstrated between capsules and dose-adjusted tablets across all six doses, as the 90% confidence interval of the ratios of the geometric least-squares means met predefined criteria. Safety and tolerability profiles were similar between both delivery forms. Treatment-emergent adverse events were mostly mild, with no apparent differences or trends in incidence by presentation or with increasing dose.
This study specifically addresses the interchangeability of dosage forms for orforglipron. While the results support pharmaceutical equivalence, these findings are limited to a Phase 1 population and do not establish long-term clinical outcomes.
How this fits prior evidence
How this fits prior evidence: This finding addresses a gap regarding the practical administration of orforglipron by confirming that tablets and capsules provide equivalent pharmacokinetic profiles. It builds upon previous coverage showing orforglipron demonstrated superior glycaemic control over dapagliflozin in type 2 diabetes, while establishing that both delivery formats are interchangeable for patients with obesity.
Researchers conducted a Phase 1 clinical trial to see if two different forms of the medication orforglipron were equal. The study involved 429 healthy adults who were either overweight or had obesity. They compared the effects of taking the medicine in tablet form versus capsule form across several different doses.
The results showed that both the tablets and capsules provided the same amount of medicine to the body. This means the two forms are bioequivalent, which is important for ensuring patients get the correct dose regardless of how the pill is manufactured. The study also looked at safety and how well people tolerated the medication over a 7-day period.
Because this was a Phase 1 trial with a small number of doses tested, these results primarily confirm that the two delivery methods are interchangeable. It does not provide long-term data on weight loss or other health outcomes. Patients should talk to their doctor about how different medication forms might affect their specific treatment plan.
What this means for you:
The study confirms that orforglipron tablets and capsules deliver the same amount of medicine to the body.
Common questions
Are the tablets and capsules of orforglipron the same?
Yes, the study found that both the tablets and capsules were bioequivalent. This means they delivered the same amount of medication to the body across all six tested doses. Because they are equivalent, the two forms can be used interchangeably for patients with obesity or who are overweight.
Is it safe to take orforglipron in different pill forms?
The study reported that both tablets and capsules had similar safety and tolerability profiles. Most of the side effects reported during the 7-day trial were mild. There were no significant differences in how well patients tolerated one form over the other.
Who was included in this study?
The study included 429 healthy adults who were either overweight or had obesity. The participants were tested across a variety of dose strengths to ensure that both the tablet and capsule versions performed consistently for those managing weight.
AIMS: To evaluate the bioequivalence of orally administered orforglipron tablets and capsules in participants with obesity or overweight who were otherwise healthy.
MATERIALS AND METHODS: This phase 1, multicenter, open-label, multiple-dose, dose-escalation study was conducted in 429 healthy adults. Study participants received each orforglipron capsule and tablet dose strength once daily for 7 days in the fasted state at capsule doses of 1, 3, 6, 12, 24, or 36 mg and corresponding tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. The primary endpoint was steady-state area under the concentration-time curve from 0 to 24 h (AUC) and steady-state maximum observed drug concentration (C ). A prespecified mixed scaling approach was applied to evaluate bioequivalence. Safety and tolerability of the tablets and capsules were also assessed.
RESULTS: Bioequivalence was demonstrated between capsules and dose-adjusted tablets across all six doses. The 90% confidence interval of the ratios of the geometric least-squares means of AUC and C between each capsule dose and corresponding tablet dose met the predefined criteria for bioequivalence. The safety profiles were similar between tablets and capsules, with no apparent differences or trends in the incidence of treatment-emergent adverse events by presentation or with increasing dose.
CONCLUSIONS: Once-daily orforglipron capsules and dose-adjusted tablets demonstrated pharmacokinetic bioequivalence at all tested doses and showed similar safety and tolerability profiles, with mostly mild treatment-emergent adverse events consistent with previous orforglipron clinical trials. ClinicalTrials .gov Identifier: NCT06440980.
